Viridian Therapeutics price target raised to $32 from $28 at Oppenheimer

Oppenheimer analyst Leland Gershell raised the firm’s price target on Viridian Therapeutics (VRDN) to $32 from $28 and keeps an Outperform rating on the shares. The firm notes the company reported a Q2 net loss of ($110.7M) vs. its estimate of $92.1M). Management maintains line of sight on veligrotug’s application submissions for thyroid eye disease in the U.S. and EU in the second half of 2025 and first half of 2026, respectively. Oppenheimer continues to see a compelling commercial opportunity as it expects veli’s efficacy, safety, and convenience advantages to challenge Amgen’s (AMGN) Tepezza following an anticipated 2026 U.S. launch. The firm says it could well see Priority Review given recent FDA Breakthrough designation.